Vivek Mishra works as an Assistant Editor with Eastern Eye and has over 13 years of experience in journalism. His areas of interest include politics, international affairs, current events, and sports. With a background in newsroom operations and editorial planning, he has reported and edited stories on major national and global developments.
Mitchell Starc bowled a decisive opening spell, leading Kolkata Knight Riders to their third Indian Premier League (IPL) title with an eight-wicket victory over Sunrisers Hyderabad in the final on Sunday.
Kolkata bowled out Hyderabad for 113, the lowest total in an IPL final. Australia's left-arm fast bowler Starc returned figures of 2-14, fulfilling his high expectations in the T20 tournament.
Starc, acquired by Kolkata for $2.98 million in the December auction, delivered two strong performances in the IPL. He also took 3-34 in the first playoff, helping to defeat the same opponent.
Kolkata's batsmen had a straightforward chase. Despite Sunil Narine's early dismissal, Rahmanullah Gurbaz scored 39, and Venkatesh Iyer remained unbeaten on 52. Their 91-run partnership ensured victory with 9.3 overs to spare.
Iyer reached his half-century in 24 balls and hit the winning runs, sparking celebrations for Kolkata, who finished top of the league table with 20 points. Skipper Shreyas Iyer was unbeaten on six when the team celebrated their victory on the pitch.
"My mom is watching from home," said Afghanistan's Gurbaz, who left the tournament midway to be with his ailing mother and returned for the playoffs. "She is feeling good now. I asked mom before the match if she wanted anything. She said just the win."
"This win is for the fans who turned up year after year and waited for ten years," said Venkatesh Iyer on the team's first title win since 2014.
Kolkata's co-owner and Bollywood actor Shah Rukh Khan attended the match and congratulated the players after recovering from a heat-related illness in the first qualifier in Ahmedabad.
It was Kolkata's second title at the venue, following their first win in 2012. A near-capacity crowd of 36,000 cheered them on.
In addition to signing Starc, Kolkata brought on Gautam Gambhir as a mentor. Gambhir had previously led the team to two titles.
Hyderabad skipper Pat Cummins won the toss and chose to bat first. Cummins, acquired for $2.5 million, became captain after leading Australia to titles in the World Test Championship and the ODI World Cup last year.
Starc took the spotlight early, bowling Indian batsman Abhishek Sharma for two in his first over. Travis Head was caught behind for his second duck in three matches off Vaibhav Arora's bowling.
Starc struck again, leaving Hyderabad's top order in trouble at 47-4 inside seven overs. Andre Russell dismissed Aiden Markram for 20, and wickets continued to fall. Heinrich Klaasen was out for 16.
Cummins, dropped on 10 by Starc, pushed the team past 100 before falling for 24 off Russell, who finished with figures of 3-19.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.